Comparison of therapeutic potential of macrophage- or mesenchymal stem cell-derived exosomes in pancreatic cancer: An updated review

Table 1 Impact of mesenchymal stem cell derived exosomes as a delivery agent in pancreatic cancer models

Type of exosome	Therapeutic agent	Target	Effect	Ref.
Bone marrow MSC-Exos	Gemcitabine	Panc-1 and MiaPaca-2 cells	Decreased vitality. Induced apoptosis	[46]
Murine bone marrow stromal cell-Exos	Paclitaxel	CFPAC-1 cells	Decreased proliferation and growth	[47]
Dental pulp MSC-Exos	Suicide genes expression and gemcitabine treatment	Panc-1 and MiaPaca-2 cells	High antiproliferative activity	[48]
Fibroblast-like MSC-Exos	KRAS siRNA	Mouse model with KrasG12D mutation	Increased survival rates	[51]
Human umbilical cord MSC-Exos	Exogenous miR-145-5p	Xenograft mouse tumor model	Inhibited proliferation. Increased apoptosis	[55]
Bone marrow MSC-Exos	Exogenous miR-145-5p	Mouse model and PDAC cell lines	Suppressed invasion and metastasis	[56]
Bone marrow MSC-Exos	Exogenous miR-128-3p	Mouse model and PDAC cell lines	Inhibits metastasis. Induces apoptosis	[57]

MSC-Exos: Mesenchymal stem cell derived exosomes; Exos: Exosomes; siRNA: Small interfering RNA; PDAC: Pancreatic ductal adenocarcinoma.